Storage Stability
Trefoil factor 1 (TFF1) is a 6.6 kDa secreted peptide produced predominantly by gastric pit mucous cells. It contains a single trefoil domain (three-leaf clover-shaped disulfide fold) that confers protease resistance and gel-forming properties. TFF1 protects gastric mucosa, promotes epithelial restitution after injury, and its expression is markedly elevated in response to ulcerogenic insults.
Mechanism of Action
- Stabilizes mucin gels by non-covalent interaction with MUC5AC, enhancing the viscous protective layer over gastric epithelium
- Promotes epithelial cell migration (restitution) into wounded areas via activation of focal adhesion kinase (FAK) and RhoA/ROCK pathways
- Stimulates EGF receptor transactivation in gastric cells, triggering ERK1/2 and PI3K/Akt survival signaling
- Inhibits anoikis (anchorage-independent apoptosis) in gastric epithelial cells during restitution
- Anti-apoptotic: TFF1 protects cells from NSAID-induced and H. pylori-induced mucosal damage
Research Findings
- TFF1 knockout mice spontaneously develop antral gastric adenomas and carcinomas by 3-6 months, establishing its tumor-suppressor role
- TFF1 administered intragastrically or IV accelerates healing of acetic acid-induced gastric ulcers in rats
- TFF1 levels markedly reduced in gastric adenocarcinoma vs surrounding normal mucosa; loss correlates with poor prognosis
- Estrogen strongly induces TFF1 in breast tissue (the original pS2 discovery); breast cancer TFF1 expression marks hormone-responsive tumors
- TFF1 nasal administration explored as cytoprotectant in radiation-induced oral mucositis in Phase I/II trials
Research Protocols
- Recombinant TFF1: 50-200 ng/mL on gastric epithelial cell monolayers for migration/wound healing assays
- Rat ulcer model: 50-200 mcg/kg IV or IG twice daily for 7 days during ulcer healing studies
- Intranasal TFF1 (TeloVac/SBG) for oral mucositis: 0.5-2 mg/day topical rinse in Phase I patients
- TFF1 IHC/ELISA: standard diagnostic use to assess gastric cancer hormone sensitivity and prognosis
Interactions
- MUC5AC mucin: physical interaction in gastric mucus layer; synergistic mucosal protection
- EGF and EGF receptor: TFF1 synergizes with EGF in epithelial migration and proliferation
- H. pylori: TFF1 upregulated in response to infection; H. pylori urease may cleave TFF1 in severe infection
Safety Profile
Endogenous protective peptide. No significant adverse effects observed in animal studies or early clinical mucositis trials. Potential concern: TFF1 paradoxically promotes invasion in established gastric carcinoma cells via CXCR4 signaling despite being a tumor suppressor in normal tissue.
Legal & Regulatory
Research/investigational; topical TFF1 products in early clinical development
Ready to dose Trefoil Factor 1?
Get the exact syringe draw
You have read the research. Now run the math. Pick your vial size and BAC water volume, get IU draw in seconds.
Open the Calculator →
Categories:
Endogenous PeptideMucosal ProtectantTrefoil Factor FamilyGastric BiologyWound HealingAnti-Ulcer
More in Tissue Repair
View all →